Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

Fig 2

Cumulative hepatocellular carcinoma (HCC) development in propensity score matched patients.

(a) 66 propensity score-matched patients in each of peg-interferon and ribavirin (PEG-IFN/RBV) and daclatasvir plus asunaprevir (DCV/ASV) groups were analyzed. (b) Patients were grouped by FIB4 index.

Fig 2